High-value efficiency Opportunity to position AXERA as a solution that dramatically reduces manual compression time and accelerates patient ambulation, appealing to hospitals seeking improved throughput and patient satisfaction in interventional procedures.

No implant risk Highlight the self-sealing, implant-free approach to access that eliminates implant-related complications, which can be a compelling differentiator when engaging facilities prioritizing safety and reduced reintervention costs.

Faster recovery Emphasize clinical benefits from RECITAL and related summaries, such as quick hemostasis and early ambulation, as a sales hook for payors and administrators focused on shorter length of stay and enhanced patient experience.

Strong funding Leverage substantial funding and a growing revenue profile to engage executives with a narrative of market validation, potential for broader adoption, and strategic partnerships in medical devices.

Tech-enabled growth Leverage digital presence and scalable deployment potential across interventional suites; emphasize compatibility with modern hospital tech stacks and the opportunity to leverage WordPress-based marketing and global reach to accelerate awareness and trials.